News

Read Our News and Insights

Featured news
  • Filter

Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)

Learn more

AnaCardio receives patent grant in Europe for AC01

Learn more

Knight Therapeutics and Helsinn Healthcare SA expand relationship and enter into exclusive license, distribution, and supply agreement for Onicit®

Learn more

Helsinn Group and ESTEVE sign a partnership agreement renewal to commercialize AKYNZEO® and ALOXI® in Germany

Learn more

Helsinn attends EORTC annual meeting 2024 with a focus on Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL)

Learn more

Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors

Learn more
Load More...
Linkedin X-twitter Vimeo

Helsinn Healthcare SA. All rights reserved. Helsinn Group 2025 ©

Exiting the US site

You are about to enter a website not intended for a US audience.
Please confirm your acceptance to continue

Continue
Cancel

Entering the US site

You are about to enter a website only intended for a US audience.
Please confirm your acceptance to continue.

Continue
Cancel

You are now leaving helsinn.com

Please click ‘Continue to external site’ if you want to continue.